



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 15/00, C12N 7/04	A1	(11) International Publication Number: WO 93/10152 (43) International Publication Date: 27 May 1993 (27.05.93)
(21) International Application Number: PCT/EP92/02591 (22) International Filing Date: 11 November 1992 (11.11.92) (30) Priority data: 9124390.7 16 November 1991 (16.11.91) GB 07/842,694 27 February 1992 (27.02.92) US (71) Applicant (for all designated States except US): SMITH-KLINE BEECHAM BIOLOGICALS S.A. [BE/BE]; 89, rue de l'Institut, B-1330 Rixensart (BE). (72) Inventors; and (75) Inventors/Applicants (for US only) : DE WILDE, Michel [BE/BE]; COHEN, Joseph [US/BE]; SmithKline Beecham Biologicals s.a., 89, rue de l'Institut, B-1330 Rixensart (BE). (74) Agent: DALTON, Marcus, Jonathan, William; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).		(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE). Published <i>With international search report.</i>
(54) Title: HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG <p style="text-align: center;"> Restriction map of the 6.8 Kb linear BglII fragment from pRIT13539 The linear fragment contains the LEU2 gene for selection of transformed yeast cells together with the RTS expression cassette. </p>		
(57) Abstract A novel hybrid protein is provided which comprises a portion of the CS protein of <i>P. falciparum</i> and the surface antigen of Hepatitis B virus. The use of this protein for vaccination purposes is disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HB₅AG

The present invention relates to a novel hybrid protein, its use in medicine, particularly in the prevention of malaria infections and vaccines
5 containing it.

Malaria, is one of the world's major health problems with 2 to 4 million people dying from the disease each year. One of the most acute forms of the disease is caused by the protozoan parasite, Plasmodium falciparum
10 which is responsible for most of the mortality attributable to Malaria.

The life cycle of P. falciparum is complex, requiring two hosts, man and mosquito for completion. The infection of man is initiated by the inoculation of sporozoites in the saliva of an infected mosquito. The
15 sporozoites migrate to the liver and there infect hepatocytes where they differentiate, via the exoerythrocytic intracellular stage, into the merozoite stage which infects red blood cells (RBC) to initiate cyclical replication in the asexual blood stage. The cycle is completed by the differentiation of a number of merozoites in the RBC into sexual stage
20 gametocytes which are ingested by the mosquito, where they develop through a series of stages in the midgut to produce sporozoites which migrate to the salivary gland.

The sporozoite stage of P. falciparum has been identified as a potential
25 target of a malaria vaccine. The major surface protein of the sporozoite is known as circumsporozoite protein (CS Protein). This protein from strain 7G8 has been cloned, expressed and sequenced (Dame et al Science 225 (1984) p593). The protein from strain 7G8 is characterised by having a central immunodominant repeat region comprising a tetrapeptide
30 Asn-Ala-Asn-Pro repeated 37 times but interspersed with four minor repeats Asn-Val-Asp-Pro. In other strains the number of major and minor repeats vary as well as their relative position. This central portion is flanked by an N and C terminal portion composed of non-repetitive amino acid sequences designated as the repeatless portion of the CS protein.

35 It has been shown that irradiated sporozoites can provide significant protection against experimental human malaria (Am. J. Trop. Med. Hyg. 24: 297-402, 1975). However, production difficulties makes the use of

-2-

irradiated sporozoite impractical from the point of view of producing a vaccine.

- Several groups have proposed subunit vaccines based on the
- 5 circumsporozoite protein. Two of these vaccines have undergone clinical testing; one is a synthetic peptide, the other is a recombinant protein (Ballou et al Lancet: i 1277 (1987) and Herrington et al Nature 328:257 (1987).
- 10 These vaccines were successful in stimulating an anti-sporozoite response. Nonetheless, the magnitude of the response was disappointing, with some vaccinees not making a response at all. Furthermore, the absence of "boosting" of antibody levels on subsequent injections and results of in
- 15 vitro lymphocyte proliferation assays suggested that T-cells of most of these volunteers did not recognise the immuno-dominant repeat. Nonetheless, one vaccinee in each study did not develop parasitemia.

- The present invention provides a new, improved antigen for use in malaria vaccines which not only produces a humoral response, but also a
- 20 cellular immune response. Preferably the antigen induces the production of neutralising antibodies against the immunodominant repeat. Most preferably, the antigen should also elicit effector T cell mediated immune responses of the CD4⁺ and CD8⁺ cytotoxic T lymphocyte (CTL) type and of the delayed type hypersensitivity type and also, preferably be able to
- 25 induce T helper (TH) memory cells.

- Accordingly, the present invention provides a hybrid protein comprising substantially all the C-terminal portion of the CS protein, four or more
- 30 tandem repeats of the immunodominant region, and the Surface antigen from Hepatitis B virus (HBsAg). Preferably the hybrid protein comprises a sequence which contains at least 160 amino acids which is substantially homologous to the C-terminal portion of the CS protein. The CS protein may be devoid of the last 12 amino-acids from the C terminal.

- 35 In particular there is provided a protein which comprises a portion of the CS protein of *P. falciparum* substantially as corresponding to amino acids 210-398 of *P. falciparum* 7G8 fused in frame via a linear linker to the N-terminal of HBsAg. The linker may comprise a portion of preS2 from

-3-

HBsAg.

The present invention also provides DNA sequences encoding the proteins of the present invention.

5

A particularly preferred embodiment is the hybrid protein designated RTS. The amino acid sequence of RTS is shown in figure 5. This hybrid consists of:

- 10 ° A methionine-residue, encoded by nucleotides 1059 to 1061, derived from the Sacchromyces cerevisiae TDH3 gene sequence. (Musti A.M. et al Gene 1983 25 133-143.
- 15 ° Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
- 20 ° A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 210 to 398 of the circumsporozoite protein (CSP) of Plasmodium falciparum strain 7G8 (Dame et al supra).
- 25 ° An amino acid (Arg) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
- 30 ° Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (9).
- 35 ° A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype).

In an alternative embodiment there is provided a hybrid protein designated RTS* which was generated using the CSP gene sequence from P. falciparum NF54 (Mol. Biochem Parisitol. 35 : 185-190, 1989) and
35 comprises substantially all of the region 207 to 395 of the CS protein from P falciparum NF54.

In particular RTS* comprises:

- A Methionine, encoded by nucleotides 1059 to 1061, derived from the TDH3 gene sequence.
- 5 • Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.
- 10 • A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 207 to 395 of the circumsporozoite protein (CSP) of *Plasmodium falciparum* strain NF54 (Mol.Biochem.Parasitol, 35:185-190, 1989).
- 15 • An amino acid (Gly) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
- 20 • Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (Nature 280:815-819, 1979).
- 25 • A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype) (Nature 280:815-819, 1979).

The amino acid sequence of RTS* is depicted in figure 9.

An expression cassette containing RTS* was constructed and comprises the following features:

- 30 • A promoter sequence, extending from nucleotide 1 through 1058, derived from the S.cerevisiae TDH3 gene.
- 35 • An open reading frame starting at nucleotide 1059 and extending to nucleotide 2330. This open reading frame is immediately followed by a translational stop codon, TAA (nucleotides 2331 to 2333). The open reading frame encodes the amino acids specifying the hybrid RTS* protein.

- A transcription termination sequence contained within the sequence extending from base pair 2334 to 3504, derived from the S. cerevisiae ARG3 gene.

5

The nucleotide sequence is depicted in figure 10.

The DNA sequences encoding the proteins of the present invention are, in a preferred embodiment flanked by transcriptional control elements, preferably derived from yeast genes and incorporated into an expression vector.

10

Such vectors are a further aspect of the invention. A preferred promoter is the promoter from the S. cerevisiae TDH3 gene Musti et al supra).

15

The invention also relates to a host cell transformed with a vector according to the invention. Host cells can be prokaryotic or eukaryotic but preferably, are yeast, such as S. cerevisiae. In such a host, the hybrid protein, for example RTS will be expressed as lipoprotein particle. The chosen recipient yeast strain preferably already carries in its genome several integrated copies of an hepatitis B S expression cassette. The resulting strain synthesises two polypeptides, S and RTS (or other hybrid protein of the invention), that spontaneously co-assemble into mixed (for example RTS, S or RTS*, S) lipoprotein particles. These particles, advantageously present the CSP sequences of the hybrid at their surface. These mixed particles also form part of the present invention. Advantageously the ratio of RTS: S or RTS* : S in these mixed particles is 1:4.

20

25

30 The present invention also relates to vaccines comprising an immunoprotective amount of a protein or particle according to the invention in admixture with a suitable diluent or carrier.

In the vaccine of the invention, an aqueous solution of the hybrid may be used directly. Alternatively, the protein with or without prior lyophilisation can be mixed or absorbed with any of the known adjuvants which include but are not limited to alum, muramyl dipeptide, saponins such as Quil A.

35

An immunostimulant may alternatively or in addition be included. In a preferred embodiment this immunostimulant will be 3 Deacylated monophosphoryl lipid A (3D-MPL).

5

3 Deacylated monophosphoryl lipid A is known from US patent No. 4,912,094 and UK patent application No. 2,220,211 (Ribi) and is available from Ribi Immunochem, Montana, USA.

- 10 The protein of the present invention may also be encapsulated into microparticles such as liposomes.

Vaccine preparation is generally described in New Trends and Developments in Vaccines, edited by Voller et al., University Park Press, 15 Baltimore, Maryland, U.S.A., 1978. Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877.

Conventional adjuvants may be used, but a preferred immunostimulant is 20 3-deacylated monophosphoryl lipid A (3D-MPL).

20

Typically when 3D-MPL is used the antigen and 3D-MPL are delivered with alum or presented in an oil in water emulsion or multiple oil in water emulsions. The incorporation of 3D-MPL is advantageous since it is a stimulator of effector T-cells responses.

25

Accordingly a preferred embodiment of the present invention provides a vaccine comprising a hybrid protein as herein described, preferably RTS, or RTS* in combination with 3D-MPL and a carrier. Typically the carrier will be an oil in water emulsion or alum.

30

In a most preferred embodiment the hybrid protein is presented as a particle or mixed particle as herein described.

The amount of the protein of the present invention present in each vaccine 35 dose is selected as an amount which induces an immunoprotective response without significant, adverse side effects in typical vaccines. Such amount will vary depending upon which specific immunogen is employed and whether or not the vaccine is adjuvanted. Generally, it is expected

-7-

- that each does will comprise 1-1000 μ g of protein, preferably 1-200 μ g most preferably 10-100 μ g. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects
- 5 will preferably receive a boost in about 4 weeks, followed by repeated boosts every six months for as long as a risk of infection exists. The immune response to the protein of this invention is enhanced by the use of adjuvant and or an immuno stimulant.
- 10 The proteins of the present invention are preferably expressed in yeast, and especially those belonging to the genus Saccharomyces.
- A further aspect of the present invention is to provide a process for the preparation of hybrid protein of the invention, which process comprises
- 15 expressing DNA sequence encoding the protein, in a suitable host, preferably a yeast, and recovering the product.
- It is particularly preferred to express the protein of the invention in a Sacchromyces strain. When RTS, for example is expressed in such strains
- 20 it spontaneously assembles into multimeric lipoprotein particles.
- These particles are highly immunogenic and induce a strong humoral response, as well as immunological memory and also are capable of inducing effector T cells of the CTL and DTH types.
- 25 A further aspect of the invention lies in a method of treating a patient susceptible to plasmodium infections by administering an effective amount of a vaccine as hereinbefore described.

Example 11. CONSTRUCTION OF THE RTS.S strain RIT4383

5 The S. cerevisiae strain, RIT4383 used for production of particles containing both the S and RTS polypeptides, carries separate expression cassettes for each protein. The S gene expression cassette has been integrated in 5 to 6 copies at least two sites in genome using a linear integration vector with homology to resident Ty retrotransposons. The
10 RTS gene expression cassette has been integrated in 2 to 3 copies at one or 2 sites in the genome, using a linear integration vector similar to the one employed for the integration of the S gene cassette. Expression from both types of cassette is driven by a promoter derived from the yeast TDH3 gene.

15

1.1 CONSTRUCTION OF THE S EXPRESSION CASSETTE AND INTEGRATIVE VECTOR (pRIT13034)

20 The S gene expression cassette (Figure 1A) identical to that found in strain RIT4376 (1) and consists of a 1058 bp TDH3 promoter fragment, 681 bp of S gene sequence, a 6 bp spacer containing an EcoR1 linker and a 1165 bp fragment carrying the Arg3 transcription terminator. The S coding sequence was derived by subcloning from a complete genomic clone (pRIT10616) of a virus of (adw serotype).

25

The structure of the Ty vector, pRIT13034, used for integration of the S expression cassette into the yeast genome, is shown in Figure 2. The construction and use of this type of vector for integration of expression cassettes in the yeast genome is described in Jacobs et al. (2). pRIT13034
30 contains the S gene cassette, the URA3 gene and the CUP1 gene inserted within a copy of a Ty element cloned on pUC9. The URA3 gene and the CUP1 gene both provide selectable markers that allow to distinguish transformed yeast colonies from untransformed colonies. pUC9 is described by Vieira & Messing (3), the URA3 fragment is from pFL44 (F. Lacroute, CNRS, Strasbourg), the CUP1 fragment is from pCUP5 (T. Butt, SKF Labs, Philadelphia), the Ty element is from Juniaux et al. (4) and the
35 S gene cassette from pRIT12353. Digestion of pRIT13034 with XhoI endonuclease liberates the 8500bp linear fragment shown in Figure 3

-9-

which can integrate into the genome by homologous recombination of the free ends with resident Ty elements.

Example 2

5

2. CONSTRUCTION OF STRAIN Y1295

The recipient strain, EJ cup1D-3d (trp1, leu2, ura3, cup1 , gal1D, MAT α) was used for initial introduction by transformation of the linear vector
10 fragment from pRIT13034. This strain contains a single disrupted cup1 locus, cup1 .

After transformation with the linear XhoI fragment, Ura⁺ colonies were isolated and screened for copper resistance. The more resistant
15 transformants had integrated two to five copies of the vector as determined by Southern blotting analysis. Two transformant colonies were retained, MS9 with an estimated 3 to 4 copies and MS23 with 4 to 5 copies of the integrated linear vector. Strain MS23 was then crossed with strain EJ cup1D-7b (trp1, ura3, cup1 , gal1D, MAT α) and a
20 haploid ascospore recovered to give strain MS23-2a.

This strain was then backcrossed to MS9 and a Leu⁻, Trp⁻ haploid segregant obtained (MS54-2c) containing 5 to 6 copies of the integrated expression cassette. Southern blotting showed that MS54-2C contained 4
25 to 5 tandem copies of the integration vector at one locus and a further single copy integrated at a different locus. All 5 to 6 copies of the expression cassette were intact as digestion of total yeast cell DNA with HindIII endonuclease to liberate the cassette fragment and Southern blotting with an S gene specific probe gave a single 3 kb band as expected.
30 A spontaneous Trp⁺ revertant of this strain was obtained, MS54-2c-T, and given the laboratory accesssion number Y1295.

Example 3 CONSTRUCTION OF THE RTS-EXPRESSION CASSETTE

35 The expression cassette for the RTS hybrid protein was constructed by a multistep cloning procedure and was cloned in the E.coli yeast shuttle vector Yep13(6) yielding a plasmid Yep13RTS (Fig.4). The structure of the cassette is shown in figure 1B. Its entire nucleotide sequence was

-10-

determined either by direct sequencing (as for the coding sequence and parts of the flanking control sequences) or by consultation of the relevant literature (as for parts of the promotor and terminator sequences). The DNA sequence is illustrated in figure 5. It contains the following

5 elements:

A promotor sequence, extending from nucleotide 1 through 1058, derived from the S. cerevisiae TDH3 gene.

10 An open reading frame starting at nucleotide 1059 and extending to nucleotide 2330. This open reading frame is immediately followed by a translational stop codon, TAA (nucleotides 2331 to 2333). The open reading frame encodes the amino acids specifying the hybrid RTS protein.

15

A transcription termination sequence contained within the sequence extending from base pair 2334 to 3504, derived from the S. cerevisiae ARG3 gene (Crabeel *et al* EMBO J. 1983 2: 205-212).

20 The amino acid sequence of the hybrid RTS protein, encoded by nucleotides 1059 to 2330 is indicated in figure 5 and contains the following elements:

25 A methionine-residue, encoded by nucleotides 1059 to 1061, derived from the TDH3 gene sequence.

Three amino acids, Met Ala Pro, derived from a nucleotide sequence (1062 to 1070) created by the cloning procedure used to construct the hybrid gene.

30

A stretch of 189 amino acids, encoded by nucleotides 1071 to 1637 representing amino acids 210 to 398 of the circumsporozoite protein (CSP) of Plasmodium falciparum strain 7G8 (8).

35 An amino acid (Arg) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.

Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to

-11-

1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (9).

5 A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype).

Example 4 CONSTRUCTION OF THE RTS CASSETTE INTEGRATIVE VECTOR pRIT13539

10 The Construction of the RTS Cassette integrative vector pRIT13539 is shown on figure 6.

The RTS expression cassette was inserted on the Ty based integrative vector pRIT13144. This vector is a derivative of pRIT12927 (2) in which
15 the LEU2 gene was inserted in the Sall site of the Ty element as a Sall-XhoI fragment isolated from the vector pCV9 (7). Thus, after insertion of the RTS expression cassette into pRIT13144, the resulting plasmid, pRIT13539, contains, in addition to the expression cassette, the yeast
20 LEU2 gene as selective marker (figure 5). Digestion of pRIT13539 with BglII endonuclease liberates a 6.800 bp linear fragment shown in figure 7 which can integrate into the genome by homologous recombination of the free ends with resident Ty elements.

Example 5 TRANSFORMATION OF STRAIN Y1295 AND
25 GENERATION OF STRAIN RIT4383 (Y1530)

To obtain a strain expressing both S and RTS proteins, Y1295 was transformed with the 6800 bp linear BglII fragment (figure 7) with selection for Leu⁺ colonies. Several integrants containing sets of both
30 expression cassettes present in the genome at various ratio were obtained. One selected transformant, expressing the RTS and S protein in a ratio of approximately 1:4 was given the official designation RIT4383 (the laboratory accession number is Y1530).

35 Example 5b Transformation of Strain Y1295 and Generation of Strain Y1631.

A similar (to RTS) construct was generated using the CSP gene sequence

-12-

derived from P.falciparum strain NF54 (Mol.Biochem.Parasitol.35:185-190, 1989). The fusion protein obtained will be designated RTS* to distinguish it from the construct obtained with the CSP derived from P.falciparum strain 7G8.

5

The sequence of the expression cassette is shown in figure 9. It contains the following elements:

- 10 • A promoter sequence, extending from nucleotide 1 through 1058, derived from the S.cerevisiae TDH3 gene.
- 15 • An open reading frame starting at nucleotide 1059 and extending to nucleotide 2330. This open reading frame is immediately followed by a translational stop codon, TAA (nucleotides 2331 to 2333). The open reading frame encodes the amino acids specifying the hybrid RTS* protein.
- 20 • A transcription termination sequence contained within the sequence extending from base pair 2334 to 3504, derived from the S. cerevisiae ARG3 gene.

This expression cassette encoding this RTS* fusion protein was transformed and integrated into the genome of yeast strain Y1295, using the same approach as described previously for the RTS construct.

- 25 Transformed clones expressing both the S and RTS* proteins were obtained. One clone was selected expressing the two proteins in a ratio of approximately 4S:1RTS*. The clone was given the laboratory accession number Y1631.

30 Example 6

PRELIMINARY CHARACTERIZATION OF THE STRAIN RIT4383

35 6.1 Analysis by immunoblotting

Cell free extracts prepared from RIT 4383 were analysed by immunoblot using various antibodies:

-13-

- a monoclonal antibody directed toward the S protein (Mab HBS1)
- a monoclonal antibody directed toward the repeat part of the RTS protein (Mab 167)
- 5 • a rabbit serum directed toward the repeat-less sequences of the RTS protein (rabbit serum no. 20).

10 In yeast strain RIT4383, two expressed products were recognized by monoclonal antibody HBS1: a 24KD protein corresponding to the S protein and a 46KD RTS hybrid protein. The RTS hybrid protein is also detected by antibodies directed toward repeat and non-repeat epitopes of the CSP. These results indicate clearly that strain RIT4383 simultaneously expresses the two S and RTS antigens at a ratio RTS/S of approximately 1:4.

15

6.2 CsC1 density gradient centrifugation

20 The formation of particles in strain RIT4383 was analyzed by CsC1 density gradient centrifugation. Crude extract (\pm 15 mg of total protein) was analyzed on a 10 ml 1.5 M CsC1 gradient (68 hours at 40.000 rpm, + 8°C in a Beckman 50 Ti rotor). Fractions (0.5ml) were collected and analyzed by a radioimmunoassay specific for HBsAg (AUSRIA), by an RTS specific ELISA and by immunoblot using an anti-HBsAg monoclonal antibody.

25

As shown in Figure 8, ELISA, RIA and Western blot peaks appear at the same fraction (no. 13) of the gradient corresponding to a buoyant density of $\rho = 1.21$ suggesting that mixed particles, containing both S and RTS monomers, are formed in this strain.

30

Example 7

PREPARATION OF THE SEED LOTS

35

Production procedure for master seed lot

Strain Y1530 (RIT4383) is first grown for 48 hours at 30°C in Petri dishes containing 20 ml sterile YNB (Difco) supplemented with

-14-

dextrose (0.1%) and 1.8% (w/v) agar (Difco). The surface growth is suspended into sterile YNB broth (Difco) supplemented with dextrose (1%) and glycerol (10%). This suspension is distributed under asptic conditions into 2 ml sterile polypropylene stoppered tubes (1 ml per tube) and stored at -70°C.

Production procedure for working seed lot

One master seed tube is rapidly thawed, and its contents are streaked with a platinum loop on Petri dishes prepared as described above. After incubation at 30°C for 63 hours, part of the surface growth is transferred to a 2 L conical flask containing 400 ml of sterile YNB broth (Difco) supplemented with dextrose (2%). The culture is incubated at 30°C for 24 hours before being centrifuged (15 min at 6300 x g) under aseptic conditions. The pellet is resuspended into sterile YNB broth (Difco) supplemented with dextrose (1%) and glycerol (10%). This is distributed under asptic conditions into 2 ml sterile glass stoppered tubes (0.5 ml per tube) and stored at -70°C.

Example 8: FERMENTATION

Preparation of the inoculum

(a) Growth on solid medium

One vial of the working seed lot is rapidly thawed and spread onto Petri dishes containing sterile YNB broth (Difco) supplemented with dextrose (1%) and 1.8% (w/v) agar (Difco). The Petri dishes are incubated for 48 hours at 30°C.

(b) Growth of inoculum

The surface growth of one Petri dish is suspended in sterile YNB broth (Difco) supplemented with dextrose (2%) and distributed equally into two conical flasks (2 L, 400 ml liquid per flask). The flasks are incubated for 24 hours at 30°C on a rotary shaker.

Fermentation

- 5 The fermentor vessel (20 L total volume) containing 5 L of dieionized water supplemented with $(\text{NH}_4)_2\text{SO}_4$ (40 g) is sterilized in-situ at 121°C for 30 minutes using clean, pre-filtered steam at 2 bar g pressure. After cooling to room temperature, the liquid volume in the fermentor is adjusted to 4L, and 1 L of filter-sterilized HB4 solution is added. The fermentation is begun by adding the inoculum (800 ml) from the two conical flasks.
- 10 The fermentation is run using the fed-batch technique whereby the culture is continuously fed with a solution of the following composition.
- 15 - 5 L HB4 solution;
 - 4 L dextrose 80% (sterilized at 121°C).
- 20 The culture density increases by aerobic growth at 30°C and pH 5 (maintained by addition of NH_4OH). Dissolved oxygen is maintained about 50% saturation by adjustment of airflow and agitation speed. The rate of addition of the feed is predetermined to maximize growth rate and minimize formation of by-product ethanol.
- 25 The fermentation is stopped after 40-90 hours. At the end of the fermentation, the total culture volume is 10-18 L, and the dry cell weight is between 30 and 100 g/L. The culture is rapidly cooled down to 15-25°C, and the yeast cells are recovered from the broth by centrifugation. The concentrated yeast cells are washed once
- 30 with phosphate buffer (50 mM) before being re-centrifuged and subsequently stored at -70°C in polyethylene bags.

HB4 Medium Composition

Component	Quantity
KH ₂ PO ₄	41.00 g
MgSO ₄ .7H ₂ O	23.50 g
CaCl ₂ .2H ₂ O	4.70 g
NaCl	0.30 g
FeCl ₃ .6H ₂ O	50.00 mg
H ₃ BO ₃	28.00 mg
MnSO ₄ .H ₂ O	22.40 mg
ZnSO ₄ .7H ₂ O	22.40 mg
Na ₂ MoO ₄ .2H ₂ O	11.20 mg
KI	5.60 mg
CaCl ₂ .6H ₂ O	5.10 mg
CuSO ₄ .5H ₂ O	2.24 mg
Biotin	2.70 mg
Folic acid	2.70 mg
Inositol	2.70 mg
Ca Pantothenate	0.54 mg
Pyridoxin.HCl	0.54 mg
Thiamin.HCl	0.54 mg
Niacin	1.20 mg
P-amino benzoic acid	0.60 mg
Riboflavin	0.60 mg
HCl (37°C)	5.00 ml
Deionized water (up to)	1.00 litre

Example 9: Extraction and Purification of RTS/SEXTRACTION PROCEDURE

5

9.1 Preparation of cell suspension

Frozen concentrated yeast cells (at -70°C) are thawed down to -30°C overnight and subsequently thawed out to 5-15°C by placing the polyethylene bags containing the cells in water (10-20°C). A yeast cell suspension is made with a phosphate buffer solution (pH 8.0) containing the following ingredients : Ethylenediamine tetraacetic acid 9EDTA), pMethylsulfonyl Fluoride (PMSF), isopropanol and tween 20.

15

9.2 Cell disruption

Cells are disrupted in a bead mill containing lead-free glass beads (0.49-0.70 mm diameter). The grinding chamber is cooled by circulation of refrigerating fluid at -20°C, in such a way that the temperature of the homogenate at the outlet of the grinding chamber does not exceed 15°C. The liquid flowrate is 6 L/hour and the agitation speed is 3000 rpm. This process is performed twice. The pH of the resulting homogenate is 6.7 to 7.5.

25

9.3 Polyethyleneglycol clarification

Polyethyleneglycol 400 (PEG 400) is added to the disrupted cell suspension to give a final concentration of 10% (30 minutes below 10°C, pH 6.1) and a partially-clarified supernatant is recovered by centrifugation (J21B Beckman centrifuge, JA10 rotor at 17,000 g for 1 hour).

30

9.4 Methanol clarification

35

Methanol is added at pH 7 to the PEG-clarified antigen to give the proportion of 1 volume of methanol for 5 volumes of PEG-clarified antigen. The clarified antigen is obtained at 17,000 g for 20

-18-

minutes by centrifugation (J21B Beckman centrifuge, JA10 rotor).

9.5 Adsorption/Desorption on colloidal silica

5 The crude antigen is adsorbed overnight onto 1.5% (w/v) colloidal silica (Aerosil 380, Degussa) at 4°C.

10 After washing (3 times) the pellet by successive centrifugation and resuspension in NaCl 0.9% (w/v), the antigen is desorbed using a 10mM pyrophosphate buffer, pH 9.5, containing 1% TWEEN 20.

15 The desorbing buffer volume corresponds to 1/8 of the methanol clarified antigen solution. The desorbed antigen solution is recovered by ultracentrifugation in a L 8.70 Beckman ultra-centrifuge rotor R19 at 50,000 g for 60 minutes.

9.6 Diafiltration

20 Before the purification steps, the desorbed antigen is washed by ultrafiltration with 5 volumes of urea 6M, NaCl 500 mM, TRIS-HCl 20 mM at pH 8.5 in order to eliminate much of the proteic and lipidic contaminants.

25 Then the buffer is exchanged in the same system (Ultrasette, FILTRON fitted with polysulfone membranes with a 300 kD nominal cut-off) with 5 volumes of TRIS-HCl 10 mM (pH 8.1).

9.7 Ion exchange chromatography on DEAE-TSK 650 (M)

30 The clarified solution is applied to an anion-exchange column (DEAE-TSK 650 (M)) equilibrated in a 10 mM TRIS-buffer, pH 8.1. After washing successively with 2 volumes of 10 mM TRIS-HCl buffer pH 8.1 and 3 volumes of 10 mM TRIS-HCl buffer pH 8.1 supplemented with 40 mM NaCl, the antigen is desorbed with less than one volume of 10 mM TRIS-HCl buffer pH 8.1 containing 150 mM NaCl. The antigen-containing fractions are pooled.

35

9.8 Hydrophobic interaction chromatography on Butyl-TSK 650 (M)

After NaCl addition up to a final concentration of 650 mM NaCl, the antigen solution is loaded on a Butyl-TSK 650 (M) column equilibrated with a 20 mM TRIS-HCl buffer, 600 mM NaCl (pH 8.1). Most of the antigen passes through while most of the impurities bind to the gel.

9.9 Concentration by ultrafiltration

The HIC pool is concentrated by ultrafiltration in an Ultrasette system (FILTRON) fitted with polysulfone membranes with a 300 kDa nominal cut-off.

9.10 Ultracentrifugation in a CsCl gradient

CsCl is added to the Butyl-TSK pool to give a final concentration of 1.5 M.

After 65 hours in a 50.2 Ti Beckman rotor at 270,000 g, the antigen-containing fractions are collected.

9.11 Size exclusion chromatography on SEPHACRYL S300 (HR Type)

In order to exchange the buffer and to eliminate low molecular weight contaminants, the antigen solution is applied to a SEPHACRYL S300 HR column. The elution buffer is 10 mM phosphate, containing 150 mM NaCl (pH 7.4).

STERILE FILTRATION

After dilution to between 150 and 400 µg Lowry/ml and pH adjustment to 6.8, the purified antigen is sterilized by filtration through a 0.22 µm sterile filter. The resulting solution contains purified RTS/S particles.

Example 10: IMMUNOLOGICAL CHARACTERIZATION OF RTS/S

10.1 Antigenicity

In order to test the antigenicity of the RTS/S particles, a number of ELISA's were performed, combining monoclonal antibodies directed against the different epitopes.

5

The monoclonal antibodies (MoAbs) used are :

- MoAb R10 :
 - specific for the repeat sequence (NANP) of the CSP region.
 - IgM isotype.
- MoAb RL117:
 - specific for the non-repeat sequence of the CSP region.
- MoAb RF1 :
 - specific for the S sequence of the HBsAg.
 - IgG1 isotype.

10

MoAbs R10 and RL117 were prepared in house by fusion of Sp2/OAg 14 myeloma cells with splenocytes of Balb/C mice immunized with partially pure RTS-like particles containing both repeat and non-repeat regions of the CSP sequence.

15

Three batches of the candidate RTS/S vaccine were analyzed : batches Nos. 24M31, 24M32 and 24M34.

10.2 Reaction with monoclonal antibody R10 (anti-repeat)

20

The anti-repeat MoAb R10 was used in a "sandwich" ELISA. Samples to be tested were incubated in microtiter plates previously coated with MoAb R10. The same MoAb coupled to peroxidase was then added. After one hour incubation at 37°C and washing, color was developed by addition of Orthophenylene-diamine-H₂O₂. Absorbance was measured at 490 nm and plotted versus the antigen concentration.

25

Results

30

The three batches : 24M31, 24M32 and 24M34 reacted positively and consistently with MoAb R10, thus confirming the presence and accessibility of the repeat epitopes on the RTS/S particles. The

-21-

amount of antigen necessary to reach 50% of maximum binding was 51.2, 38.2 and 60.6 ng for batches 24M31, 24M31 and 24M34 respectively.

5 10.3 Reaction with monoclonal antibody RL117 (anti-repeatless)

10 The reactivity of MoAb RL117 with RTS,S particles was analyzed in a "sandwich" ELISA test. MoAb RL117 was coupled to peroxidase and used for the detection of the RTS/S particles, while MoAb R10, specific for the repeat region, was used for the capture of particles.

15 Briefly, samples to be tested were incubated in microtiter plates previously coated with MoAb R10. RL117 coupled to peroxidase was then added, and, after one hour incubation at 37°C and washing, the coloration was developed by addition of Orthophenylene-diamine-H₂O₂. Absorbance was measured at 490 nm and plotted versus the antigen concentration.

20 Results

25 The three batches : 24M31, 24M32 and 24M34 reacted positively and consistently with MoAbs RL117 and R10, thus confirming the presence and accessibility of repeat and ono-repeat epitopes on the same RTS/S particles. The amount of antigen necessary to reach 50% of maximum binding was 169.2, 117.6 and 181.1 ng for batches 24M31, 24M32 and 24M34 respectively

10.4 Reaction with monoclonal antibody RF1 (anti-S)

30 The presence of S-epitopes in RTS/S particles was shown by a "sandwich" ELISA test, using MoAb RF1 coupled to peroxidase for detection. The R10 MoAb was used directly onto the microtiter plates in order to capture the RTS,S particles.

35 In summary, samples to be tested were incubated in microtiter plates previously coated with MoAb R10. MoAb RF1 coupled to peroxidase was then added. After incubation at 37°C for 1 hour and washing, color development was allowed by addition of

-22-

Orthophenylene-diamine-H₂O₂. Absorbance was measured at 490 nm and plotted versus the antigen concentration.

Results

5

10

The three batches : 24M31, 24M32 and 24M34 reacted positively and consistently with MoAbs RF1 and R10, thus confirming the presence and accessibility of the repeat and Sepitopes on the same RTS/S particles. The amount of antigen necessary to reach 50% of maximum binding was 52.3, 55.2 and 106.2 ng for batches 24M31, 24M32 and 24M34 respectively.

Example 11: IMMUNOGENICITY IN VIVO OF RTS/S PARTICLES

15 11.1 Immunogenicity studies

Studies on the immunogenicity of (RTS,S) particles were performed in mice and in Cercopithecus aethiop monkeys.

20

25

30

35

In mice, anti-CSP antibodies were analyzed by ELISA test using the R32tet32 antigen for the detection of the anti-repeat antibodies. R32tet32 consists of 32 copies of the NANP (major) repeat fused to a 32 amino acid portion of the tetracyclin resistance gene of plasmid pBR322. The recombinant antigen is produced in Escherichia coli. Antibodies (Abs) directed against the non repeated sequence of the CS protein were measured by ELISA test using the RLF antigen. The RLF antigen consists of the complete CS protein flanking region devoid of repeat fused to the first 81 amino acids of the NS1 protein of influenza virus. The RLF antigen is produced in E. coli. Mice sera were serially diluted, starting at 1:100, and titers are expressed as the reciprocal of the dilution corresponding to an optical density of 1.0 in the ELISA test (1). Measurements of anti-CSP Abs were performed on individual sera and the geometric mean titer (GMT) was calculated.

In order to analyze the anti-carrier response, anti-HBs antibody titers were also measured (pooled sera only).

-23-

In mice experiments, Balb/C mice (H-2d haplotype) usually used for the immunogenicity of HBsAg were also used to evaluate the immunogenicity of RTS,S particles. The intraperitoneal (i.p.) and the subcutaneous (s.c.) routes of immunization were compared and the effect of the immunostimulant 3-deacylated monophosphoryl lipid A (3D-MPL) on the immune response was also tested.

The immunogenicity of the (RTS,S) vaccine was also tested in a similar way in *Cercopithecus aethiops* monkeys.

Selected individual or pooled sera were also tested for their capacity to inhibit the in vitro invasion of a human hepatoma cell line (HepG2) by *P. falciparum* sporozoites (ISI assay (2)).

11.2 Immunogenicity in mice

EXPERIMENT 1 : Immunogenicity of clinical (RTS,S) batches adsorbed on A1(OH)₃

Method

Immunization :

Groups of 10 Balb/C mice were injected twice intraperitoneally at one month interval with 1 µg of each of three (RTS,S) batches previously adsorbed on A1(OH)₃ (batches 24M/31, 24M/32 and 24M/34). Control mice were injected with HBsAg (Engerix-B, batch ENG611B4). On days 30 and 45, the mice were bled and the antibody titers were measured on individual sera.

Serological methods :

The anti-R32tet32 and the anti-RLF titers were measured by ELISA using respectively R32tet32 and RLF as coating antigens. The microplates were incubated with the serum sample (12 two-fold serial dilutions starting at 1:100) to be tested. Mouse Abs were reacted with biotinylated anti-mouse Ig followed by streptavidin : biotinylated horseradish peroxidase complex and orthophenylene-

-24-

diamine/H₂O₂. The optical density was measured at 490 nm. The titers were expressed as the reciprocal of the dilution corresponding to an optical density of 1.0 (50 % maximal binding). For each group of mice, the geometric mean titer (GMT) was calculated.

5 The anti-HBs antibody titer was calculated according to the Hollinger formula (3) and expressed in mIU/ml.

Results

10 Anti-CSP response :

Strong anti-R32tet32 and anti-RLF responses were observed for each (RTS,S) batch tested. No significant difference between the batches was noted. A remarkable booster effect was observed after
15 the second dose. Mice immunized with HBsAg ("Engerix-B") were used as negative control in this experiment.

Anti-HBs response :

20 The (RTS,S) batches induce antibodies directed against the HBsAg carrier protein. The assay was performed on pooled sera only.

EXPERIMENT 2 : Effect of the immunostimulant 3D-MPL on the immunogenicity of (RTS,S) particles in Balb/C mice.

25 We analyzed the effect of the 3D-MPL on the immunogenicity of the (RTS,S) vaccine in mice. Both the intraperitoneal (i.p.) and the subcutaneous (s.c.) routes of immunization were tested.

30 A. Immunization by the ip route

Method

Immunization:

35

Groups of 10 Balb/C mice were injected twice intraperitoneally at one month interval with 1 µg of (RTS,S) (batch 24M/34) adsorbed on Al(OH)₃ alone or on Al(OH)₃ + 3D-MPL (50 µg/dose). Control mice

-25-

were injected with NaCl 150 mM. One days 30 and 45, the mice were bled and the antibody titers measured on individual sera.

Serological method:

5

The serological methods were the same as in the first experiment described above.

Results

10

Anti-CSP response:

15

The (RTS,S) vaccine batch induces strong anti-R32tet32 and anti-RLF responses in both formulations. In all cases, a significant booster effect is observed following the second immunization. Titers obtained with the formulation containing 3D-MPL are in all cases higher than the aluminium alone formulation, and a statistically significant increase was observed in the primary anti-R32tet32 response ($p = 0.02$). A group of mice injected with NaCl 150 mM was used as negative control in this experiment.

20

Anti-HBs response:

25

Both formulations of the (RTS,S) vaccine, injected by the i.p. route, induced a strong anti-HBs response. A significant booster effect was observed following second immunization with either formulation.

B. Immunization by the s.c. route

30

Method

Immunization:

35

Groups of 10 Balb/C mice were injected twice subcutaneously at one month interval with 1 μ g of (RTS,S), (batch 24M/34) adsorbed on Al(OH)₃ alone or on Al(OH)₃ + 3D-MPL (50 μ g/dose). Control mice were injected with NaCl 150 mM. One days 30 and 45, the

-26-

mice were blend and the antibody titers measured on individual sera.

The serological methods were the same as in the first experiment described above.

Results

Anti-CSP response:

The (RTS,S) vaccine batch induced positive response against R32tet32 and RLF in both formulations. In all cases, a significant booster effect was observed following the second immunization. Statistically significant higher titers were observed with the 3D-MPL formulation on day 45, both for the anti-R32tet32 and anti-RLF responses ($p = 0.18$ and $p = 2.9$ respectively). In general, however, titers were lower than those obtained with the i.p. route. A group of mice injected with NaCl 150 mM was used as negative control in this experiment.

Anti-HBs response:

Both formulations of the (RTS,S) vaccine, injected by the s.c. route induced a good anti-HBs response. A significant booster effect was observed following second immunization with either formulation. As observed for the anti-CSP responses, the anti-HBs response was lower by this route of immunization as compared to the i.p. route.

11.3 Immunogenicity in Cercopithecus aethiops

The immunogenicity was evaluated in Cercopithecus aethiops monkeys with clinical batch 24M/32 adsorbed on Al(OH)₃.

Methods

Immunization:

Five monkeys wer injected intramuscularly on days 0, 28 and 84

-27-

with 20 µg of (RTS,S) particles adsorbed on Al(OH)₃ (0.5 mg Al+++). The animals were bled on days 0, 14, 28, 42, 56, 66 and 98. Antibodies directed against R32tet32, RLF and HBs antigens were measured.

5

Serological methods:

A anti-R32tet32 and the anti-RLF antibody titers were measured by ELISA using respectively the R32tet32 and the RLF antigens coated on microplates. The plates were then incubated with the serum sample to be tested (12 two-fold serial dilutions starting at 1:10). Monkey antibodies were detected by biotinylated anti-human Ig followed by streptavidin biotinylated horseradish peroxidase complex and orthophenylenediamine/H₂O₂. The optical density was measured at 490 nm. The titers were expressed as the reciprocal of the dilution corresponding to an optical density of 1.0 (50% maximal binding). For each group, the geometric mean titer (GMT) was calculated. The anti-HBs antibody titers were calculated according to the Hollinger formula (Hollinger et al., 1982) and expressed in mIU/ml.

10

15

20

Results

Anti-CSP response:

25

30

The (RTS,S) vaccine induced a positive response against both R32tet32 and RLF antigens in all 5 monkeys. A significant booster effect was observed 14 days following second immunization (day 42). A slow decrease of antibody titers was then observed up to the third immunization. The titers again increase 14 days following the third immunization (day 98), except in the case of the anti-RLF response of monkey Jo 352.

35

The anti-R32tet32 titers reached after the third immunization (day 98) are not however higher than those observed after the second immunization (day 42).

In the case of the anti-RLF response (with the exception of monkey

-28-

JO 353), an increase of titers is observed following the third immunization (day 98) relative to post second immunization levels (day 42).

5 **Anti-HBs response:**

All monkeys raised an anti-HBs response with significant booster effects following second (day 42) as well as third (day 98) immunization.

10

Biological activity of antibodies raised against the (RTS,S) particle

15

As a measure of the biological function of the antibodies induced by the (RTS,S) vaccine, pooled mice and individual monkeys sera were tested by the Inhibition of Sporozoite Invasion (ISI) assay (Hollingdale et al., 1984). This assay measured the capacity of the anti-CSP antibodies to inhibit the in vitro invasion of a human hepatoma cell line (HepG2) by P. falciparum sporozoites.

20

Results

25

The results of this experiment are presented in Tables 1 and 2. The ISI data are expressed as % inhibition relative to the activity of a pre-immune control serum taken as 0% inhibition. For reference, the anti-R32tet32 and RLF antibody titers of the tested sera are included. Table 1 shows that all mice sera tested have very high ISI activity. Table 2 shows that all 5 monkeys have also a very ISI activity on day 98 compared with the corresponding immune serum.

30

Conclusion

35

The (RTS,S) particles induced, both in mice and monkeys, a high antibody response directed against the repeat and non-repeat epitopes of the CSP and against the S protein of the HBsAg carrier.

The primary antibody response in mice was enhanced by the presence of 3D-MPL.

Antibody titers obtained after intraperitoneal injection were higher than those obtained after immunization by the subcutaneous route.

- 5 5 The antibodies elicited in the two animal species effectively
prevented invasion of cultured human hepatoma cells by
6 P. falciparum sporozoites.

-30-

Table 1: ISI activity of sera from Balb/C mice immunized with TS.S

Pool of Mice sera	A-R32tet32 Titer	A-RLF Titer	ISI (%)
Pool i.p A1+3D-MPL Day 45	606544	242408	100%
Pool i.p Alum only Day 45	87005	160284	98%
Pool i.p A1+3D-MPL Day 45	15333	99002	94%
Pool s.c A1+3D-MPL Day 45	5102	20453	86%
Pool of Negative Controls	205	205	0%

-31-

Table 2: ISI activity of individual monkey sera immunized with RTS,S

Monkey #	Serum	A-R32tet32 titer	A-RLF titer	ISI (%)
J0 352	DAY 0	<50	<50	0%
	DAY 98	1762	1250	98%
J0 353	DAY 0	<50	<50	0%
	DAY 98	1574	32218	90%
J0 354	DAY 0	<50	<50	0%
	DAY 98	3751	31034	98%
J0 356	DAY 0	<50	<50	0%
	DAY 98	1495	18544	95%
J0 357	DAY 0	<50	<50	0%
	DAY 98	1420	30727	98%

Reference

- 5 (1) Harford N, Cabezon T, Colau B, et al., "Construction and Characterization of a *Saccharomyces Cerevisiae* Strain (RIT4376) Expressing Hepatitis B Surface Antigen", Postgrad Med J 63, Supp. 2: 65-70, 1987.
- 10 (2) Jacobs E, Rutgers T, Voet P, et al., "Simultaneous Synthesis and Assembly of Various Hepatitis B Surface Proteins in *Saccharomyces cerevisiae*", Gene 80: 279-291, 1989.
- 15 (3) Vieira J and Messing J, "The pUC plasmids, an M13mp7-Derived System for Insertion Mutagenesis and Sequencing with Synthetic Universal Primers", * Gene 19: 259-268, 1982.
- (4) Juniaux Embo J 1: 1125-1131, 1982.
- 20 (5) Hinnen A, Hicks JB, and Fink GR, "Transformation of Yeast", Proc Natl Acad Sci USA 75: 1929-1933, 1980.
- (6) Broach JR, Strathern JN, and Hicks JB, "Transformation in Yeast Development of a Hybrid Cloning Vector and Isolation of the CAN 1 Gene", Gene 8: 121-133, 1979.
- 25 (7) Zhang H, et al., "Double Stranded SDNA Sequencing as a Choice for DNA Sequencing", Nucleic Acids Research 16: 1220, 1988.
- 30 (8) Dame JB, Williams JL, Mc Cutchan TF, et al., "Structure of the Gene Encoding the Immunodominant Surface Antigen on the Sporozoites of the Human Malaria Parasite *Plasmodium falciparum*", Science 225: 593-599, 1984.
- 35 (9) Valenzuela P, Gray P, Quiroga M, et al., "Nucleotide Sequences of the Gene Coding for the Major Protein of Hepatitis B Virus Surface Antigen", Nature 280: 815-819, 1979.

-33-
Claims

1. A hybrid protein comprising substantially all the C-terminal portion of the CS protein of Plasmodium, four or more tandem repeats of the CS protein immunodominant region, and the surface antigen from Hepatitis B Virus (HBsAg).
5
2. A hybrid protein comprising a sequence of CS protein of P.falciparum substantially as corresponding to amino acids 210-398 of P.falciparum 7G8 CS protein or 207-395 of P. falciparum NF54 CS protein fused in frame via a linear linker to the N-terminal of HBsAg.
10
3. A hybrid protein as claimed in claim 1 or 2 wherein the CS protein is fused to HBsAg.
15
4. A hybrid protein comprising the following amino acid sequences:
 - a) an N-terminal methionine residue
 - b) Met Ala Pro
 - 20 c) a stretch of 189 amino acids corresponding to amino acids 210 to 398 of CS protein P.falciparum 7G8 or 207-395 of CS protein P. falciparum NF54
 - d) Arg
 - e) Pro Val Thr Asn from hepatitis B Pre S₂ protein.
 - 25 f) a stretch of 226 amino acids specifying the S protein of hepatitis B virus
6. The hybrid protein designated RTS.
- 30 7. The hybrid protein designated RTS*.
8. A DNA sequence encoding a hybrid protein as claimed in claims 1 to 7.
- 35 9. A vector containing a DNA sequence as claimed in claim 8 said sequence being linked to transcriptional control elements.
10. A host transformed with a vector of claim 9.

11. A host as claimed in claim 10 wherein the host is S. cerevisiae.
12. A host as claimed in claim 11 additionally transformed with a
5 gene encoding the Hepatitis B surface antigen.
13. A multimeric lipoprotein particle comprising a hybrid protein of
claims 1 to 7.
- 10 14. A mixed multimeric lipoprotein particle comprising a hybrid
protein of claims 1 to 7 and Hepatitis B surface antigen.
15. A mixed multimeric lipoprotein of claim 14 comprising RTS, or
RTS* and the surface antigen of Hepatitis B virus.
- 15 16. A particle as claimed in claim 14 or 15 wherein the ratio of hybrid
protein to surface antigen is 1:4.
17. A vaccine comprising an immunoprotective amount of a particle or
20 protein according to any of claims 1 to 7 or claims 13 to 16 in admixture
with a suitable diluent or carrier.
18. A vaccine as claimed in claim 17 additionally comprising 3-
Deacylated monophosphoryl lipid A.
- 25 19. A vaccine as claimed in claim 18 additionally comprising alum.
20. A vaccine as claimed in claim 18 presented in an oil in water
emulsion.
- 30 21. A method of treating a patient susceptible to plasmodium
infections comprising administering an effective amount of vaccine
according to any of claims 17 to 20.
- 35 21. A process for the production of a hybrid protein according to any of
claims 1 to 7 which process comprises expressing a DNA sequence
encoding the protein in a suitable host and recovering the product.

-35-

22. A process for the production of particles as claimed in claims 12 to 15 comprising expressing a DNA sequence encoding a protein of claims 1 to 7 and hepatitis B surface antigen in a *Sacchromyces* strain.

1/19

Restriction endonuclease map of (A) the S expression cassette and (B) the RTS expression cassette.
The extend of each coding sequence is indicated by the black bar.




Fig.1(A)





Fig.1(B)

2/19


Construction of plasmid pRIT13034

Digestion with XhoI endonuclease liberates a 8.5 Kb linear DNA fragment carrying the S expression cassette for integration into the yeast chromosome by homology of the free ends with resident Ty elements.

**Fig.2**

3/19

Restriction map of the 8.5 Kb linear XhoI fragment from pRIT13034
The linear fragment contains the URA3 and CUP1 genes for selection of transformed yeast cells together with the S expression cassette.

**Fig.3**

4/93

Construction of the RTS expression cassette and its cloning in plasmid Yep13.




Fig.4

SUBSTITUTE SHEET

5/19

Figure 5: Nucleotide sequence of the RTS expression cassette and predicted translation product of the RTS-HBsAg hybrid protein.
The translation product initiated from the TDH3 ATG codon is shown below the DNA sequence.

```

      10              30              50
AAGCTTACCAGTTCTCACACGGAACACCACTAATGGACACAAATTCGAAATACTTTGACC
      70              90              110
CTATTTTCGAGGACCTTGTACCTTGAGCCCAAGAGAGCCAAGATTTAAATTTTCCTATG
      130             150             170
ACTTGATGCAAATTCCCAAAGCTAATAACATGCAAGACACGTACGGTCAAGAAGACATAT
      190             210             230
TTGACCTCTTAACTGGTTCAGACGCGACTGCCTCATCAGTAAGACCCGTTGAAAAGAACT
      250             270             290
TACCTGAAAAAACGAATATATACTAGCGTTGAATGTTAGCGTCAACAACAAGAAGTTTA
      310             330             350
ATGACGCGGAGGCCAAGGCAAAAAGATTCCCTTGATTACGTAAGGGAGTTAGAATCATTTT
      370             390             410
GAATAAAAAACACGCTTTTTTCAGTTCGAGTTTATCATTATCAATACTGCCATTTCAAAGA
      430             450             470
ATACGTAAATAATTAATAGTAGTGATTTTCCTAACTTTATTTAGTCAAAAATTAGCCTTT
      490             510             530
TAATTCCTGCTGTAACCCGTACATGCCCAAAATAGGGGGCGGGTTACACAGAATATATAAC
      550             570             590
ATCGTAGGTGTCTGGGTGAACAGTTTATCCCTGGCATCCACTAAATATAATGGAGCTCGC
      610             630             650
TTTTAAGCTGGCATCCAGAAAAAAAAGAATCCAGCACCAAAATATTGTTTCTTCACC
      670             690             710
AACCATCAGTTCATAGGTCCATTCTCTTAGCGCAACTACAGAGAACAGGGGCACAAACAG
      730             750             770
GCAAAAAACGGGCACAACCTCAATGGAGTGATGCAACCTGCCTGGAGTAAATGATGACAC
      790             810             830
AAGGCAATTGACCCACGCATGTATCTATCTATTTCTTACACCTTCTATTACCTTCTGC

```

SUBSTITUTE SHEET

6/19

850	870	890
TCTCTCTGATTGGAAGCTGAAAAAAGGTTGAAACCAGTCCCTGAAATTATTC		
910	930	950
CCTACTTGACTAATAAGTATATAAAGACGGTAGGTATTGATTGTAATTCTGTAAATCTAT		
970	990	1010
TTCTTAACTTCTTAAATTCTACTTTTATAGTTAGTCTTTTTTTTAGTTTTAAACACCA		
1030	1050	1070
AGAACTTAGTTTCGAATAAACACACATAAACAAACAAATGATGGCTCCCGATCCTAATG MetMetAlaProAspProAsnA		
1090	1110	1130
CAAATCCAAATGCAAACCCAAATGCAAACCCAAACGCAAACCCCAATGCAAATCCTAATG laAsnProAsnAlaAsnProAsnAlaAsnProAsnAlaAsnProAsnAlaAsnProAsnA		
1150	1170	1190
CAAACCCCAATGCAAATCCTAATGCAAATCCTAATGCCAATCCAAATGCAAATCCAAATG laAsnProAsnAlaAsnProAsnAlaAsnProAsnAlaAsnProAsnAlaAsnProAsnA		
1210	1230	1250
CAAACCCAAACGCAAACCCCAATGCAAATCCTAATGCCAATCCAAATGCAAATCCAAATG laAsnProAsnAlaAsnProAsnAlaAsnProAsnAlaAsnProAsnAlaAsnProAsnA		
1270	1290	1310
CAAACCCCAATGCAAACCCCAATGCAAACCCCAATGCAAATCCTAATAAAACAATCAAG laAsnProAsnAlaAsnProAsnAlaAsnProAsnAlaAsnProAsnLysAsnAsnGlnG		
1330	1350	1370
GTAATGGACAAGGTCACAATATGCCAAATGACCCAAACCGAAATGTAGATGAAAAATGCTA lyAsnGlyGlnGlyHisAsnMetProAsnAspProAsnArgAsnValAspGluAsnAlaA		
1390	1410	1430
ATGCCAACAATGCTGTAAAAATAATAATAACGAAGAACCAAGTGATAAGCACATAGAAC snAlaAsnAsnAlaValLysAsnAsnAsnAsnGluGluProSerAspLysHisIleGluG		
1450	1470	1490
AATATTTAAAGAAAATAAAAAATTCTATTTCAACTGAATGGTCCCATGTAGTGTAACCTT lnTyrLeuLysLysIleLysAsnSerIleSerThrGluTrpSerProCysSerValThrC		
1510	1530	1550
GTGGAAATGGTATTCAAGTTAGAATAAAGCCTGGCTCTGCTAATAAACCTAAAGACGAAT ysGlyAsnGlyIleGlnValArgIleLysProGlySerAlaAsnLysProLysAspGluL		
1570	1590	1610
TAGATTATGAAAATGATATTGAAAAAAAATTTGTAAAATGGAAAAGTGCTCGAGTGTGT euAspTyrGluAsnAspIleGluLysLysIleCysLysMetGluLysCysSerSerValP		
1630	1650	1670

SUBSTITUTE SHEET

7/19

TTAATGTCGTAAGTAGTCGACCTGTGACGAACATGGAGAACATCACATCAGGATTCCTAG
heAsnValValAsnSerArgProValThrAsnMetGluAsnIleThrSerGlyPheLeuG

1690

1710

1730

GACCCCTGCTCGTGTTACAGGCGGGGTTTTCTTGTGACAAGAATCCTCACAATACCGC
lyProLeuLeuValLeuGlnAlaGlyPhePheLeuLeuThrArgIleLeuThrIleProG

1750

1770

1790

AGAGTCTAGACTCGTGGTGGACTTCTCTCAATTTCTAGGGGGATCACCCGTGTGCTTG
lnSerLeuAspSerTrpTrpThrSerLeuAsnPheLeuGlyGlySerProValCysLeuG

1810

1830

1850

GCCAAAATTCGCAGTCCCCAACCTCCAATCACTACCAACCTCCTGTCCTCCAATTTGTC
lyGlnAsnSerGlnSerProThrSerAsnHisSerProThrSerCysProProIleCysP

1870

1890

1910

CTGGTTATCGCTGGATGTGTCTGCGGCGTTTTATCATATTCCTCTTCATCCTGCTGCTAT
roGlyTyrArgTrpMetCysLeuArgArgPheIleIlePheLeuPheIleLeuLeuLeuC

1930

1950

1970

GCCTCATCTTCTTATTGGTTCTTCTGGATTATCAAGGTATGTTGCCCGTTTGCTCTTAA
ysLeuIlePheLeuLeuValLeuLeuAspTyrGlnGlyMetLeuProValCysProLeuI

1990

2010

2030

TTCCAGGATCAACAACAACCAATACGGGACCATGCAAAACCTGCACGACTCCTGCTCAAG
leProGlySerThrThrThrAsnThrGlyProCysLysThrCysThrThrProAlaGlnG

2050

2070

2090

GCAACTCTATGTTTCCCTCATGTTGCTGTACAAAACCTACGGATGGAAATTGCACCTGTA
lyAsnSerMetPheProSerCysCysCysThrLysProThrAspGlyAsnCysThrCysI

2110

2130

2150

TTCCCATCCCATCGTCCTGGGCTTTTCGCAAAATACCTATGGGAGTGGGCCTCAGTCCGTT
leProIleProSerSerTrpAlaPheAlaLysTyrLeuTrpGluTrpAlaSerValArgP

2170

2190

2210

TCTCTTGGCTCAGTTTACTAGTGCCATTTGTTTCAAGTGGTTCGTAGGGCTTTCCCCCACTG
heSerTrpLeuSerLeuLeuValProPheValGlnTrpPheValGlyLeuSerProThrV

2230

2250

2270

TTTGGCTTTCAGCTATATGGATGATGTGGTATTGGGGGCCAAGTCTGTACAGCATCGTGA
alTrpLeuSerAlaIleTrpMetMetTrpTyrTrpGlyProSerLeuTyrSerIleValS

2290

2310

2330

GTCCCTTTATACCGCTGTTACCAATTTTCTTTTGTCTCTGGGTATACATTTAACGAATT
erProPheIleProLeuLeuProIlePhePheCysLeuTrpValTyrIleEnd

2350

2370

2390

CAAGCTGAAACAATTCAAAGGTTTTCAAATCAATCAAGAAGTGTCTCTGTGGCTGATCC

SUBSTITUTE SHEET

8/19

2410 2430 2450
AAACTACAAATTTATGCATTGTCTGCCAAGACATCAAGAAGAAGTTAGTGATGATGTCTT
2470 2490 2510
TTATGGAGAGCATTCCATAGTCTTTGAAGAAGCAGAAAAACAGATTATATGCAGCTATGTC
2530 2550 2570
TGCCATTGATATCTTTGTTAATAATAAAGGTAATTTCAAGGACTTGAAATAATCCTTCTT
2590 2610 2630
TCGTGTTCTTAATAACTAATATATAAATACAGATATAGATGCATGAATAATGATATACAT
2650 2670 2690
TGATTATTTTGCAATGTCAATTAAAAAATGTTAGTAAACTATGTTACATTCCA
2710 2730 2750
AGCAAATAAAGCACTTGGTTAAACGAAATTAACGTTTTTAAGACAGCCAGACCGCGGTCT
2770 2790 2810
AAAAATTTAATATACACTGCCAACAAATTCCTTCGAGTTGTCCAATTTCACTACTTTTA
2830 2850 2870
TATTTTCATCAACTTCAGCAGATTCAACCTTCTCACATAGAACATTGGAATAAACAGCCT
2890 2910 2930
TAACACCACTTTCAAGTTTGCACAGCGTAATATGAGGAATTTGTTTGTACAACACAACC
2950 2970 2990
CTTTAATTTTCTCATTGTTTTCATCAATTATGCATCCATCTTTATCTTTAGACAGTTCCA
3010 3030 3050
CTACAATAGCAATAGTTTTTTCATCCCAACATAGTTTTTCGAGCCTAAAATTCAGTTTGT
3070 3090 3110
CGGTCGTTTTTACCTGCGTATTTTGGTTATTACCAGAGCCTTGTGCATTTTCTATGCGGT
3130 3150 3170
TGTTATTGTACTCCGTTATCTGGTCAGTGTATCTGTTACAATATGATTCCACAACCTTTT
3190 3210 3230
TGCCCTCTTTTTCACGGGACGACATGACATGACCTAATGTTATATGAAGTTCTTCTGAAC
3250 3270 3290
TTTTCCACTAGCTAGTAAATGCTTGAATTTCTCAGTCAGCTCTGCATCGCTAGCAATACA
3310 3330 3350
CCTCTTGACCAATTCAATAATTTTCATCGTAGTTTTCTATTTAGCTGAGATATATGTAGGT


SUBSTITUTE SHEET

3370 9/19 3390 3410
TTAATTAACTTAGCGTTTTTTGTTGATTATTGTTGCCTTTACCAACTATTTTCTCACAG
3430 3450 3470
TAGGTTTGTAATCTAAGCTCCTTCTGAACGCTGTCTCAATTCATCATCTTTCGGGATCT
3490
CTGGTACCAAAATTGGATAAGCTT

10/19

Construction of plasmid pRIT13539

Digestion with BglII endonuclease liberates a 6.8 Kb linear DNA fragment carrying the RTS expression cassette for integration into the yeast chromosome by homology of the free ends with resident Ty elements.

**Fig.6**

Restriction map of the 6.8 Kb linear BglIII fragment from pRIT13539
 The linear fragment contains the LEU2 gene for selection of transformed yeast cells together with the RTS expression cassette.




Fig. 7

12/19

Cscl density analysis of a cell-free extract prepared from strain RIT4383. Fractions were analyzed by a radioimmunoassay specific for HBsAg (AUSRIA), and by an RTS-specific ELISA. The top panel shows the immunoblot analysis of fractions using an anti-S Mab. The buoyant density (ρ) of the peak fraction was calculated from a measure of its refractive index.




Fig.8

73/19

Figure 9: Nucleotide Sequence of the RTS* expression cassette and predicted translation product of the hybrid protein.

```

Met Met Ala Pro Asp Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala
1           5           10           15

Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala
20           25           30

Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala
35           40           45

Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala
50           55           60

Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Lys
65           70           75           80

Asn Asn Gln Gly Asn Gly Gln Gly His Asn Met Pro Asn Asp Pro Asn
85           90           95

Arg Asn Val Asp Glu Asn Ala Asn Ala Asn Ser Ala Val Lys Asn Asn
100          105          110

Asn Asn Glu Glu Pro Ser Asp Lys His Ile Lys Glu Tyr Leu Asn Lys
115          120          125

Ile Gln Asn Ser Leu Ser Thr Glu Trp Ser Pro Cys Ser Val Thr Cys
130          135          140

Gly Asn Gly Ile Gln Val Arg Ile Lys Pro Gly Ser Ala Asn Lys Pro
145          150          155          160

Lys Asp Glu Leu Asp Tyr Ala Asn Asp Ile Glu Lys Lys Ile Cys Lys
165          170          175

Met Glu Lys Cys Ser Ser Val Phe Asn Val Val Asn Ser Ser Ile Gly
180          185          190

Leu Gly Pro Val Thr Asn Met Glu Asn Ile Thr Ser Gly Phe Leu Gly

```

74/19

195	200	205
Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu		
210	215	220
Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu		
225	230	235 240
Gly Gly Ser Pro Val Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser		
245	250	255
Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp		
260	265	270
Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys		
275	280	285
Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val		
290	295	300
Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Asn Thr Gly Pro Cys Lys		
305	310	315 320
Thr Cys Thr Thr Pro Ala Gln Gly Asn Ser Met Phe Pro Ser Cys Cys		
325	330	335
Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser		
340	345	350
Ser Trp Ala Phe Ala Lys Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe		
355	360	365
Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu		
370	375	380
Ser Pro Thr Val Trp Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly		
385	390	395 400
Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro Leu Leu Pro Ile		
405	410	415

SUBSTITUTE SHEET

15/19

Phe Phe Cys Leu Trp Val Tyr Ile

420

AAGCTTACCA GTTCTCACAC GGAACACCAC TAATGGACAC AAATTCGAAA TACTTTGACC
60

CTATTTTCGA GGACCTTGTC ACCTTGAGCC CAAGAGAGCC AAGATTTAAA TTTTCCTATG
120

ACTTGATGCA AATTCCCAAA GCTAATAACA TGCAAGACAC GTACGGTCAA GAAGACATAT
180

TTGACCTCTT AACTGGTTCA GACGCGACTG CCTCATCAGT AAGACCCGTT GAAAAGAACT
240

TACCTGAAAA AAACGAATAT ATACTAGCGT TGAATGTTAG CGTCAACAAC AAGAAGTTTA
300

ATGACGCGGA GGCCAAGGCA AAAAGATTCC TTGATTACGT AAGGGAGTTA GAATCATTTT
360

GAATAAAAAA CACGCTTTTT CAGTTCGAGT TTATCATTAT CAATACTGCC ATTTCAAAGA
420

ATACGTAAAT AATTAATAGT AGTGATTTTC CTAAC TTAT TTAGTCAAAA ATTAGCCTTT
480

TAATTCTGCT GTAACCCGTA CATGCCCAAA ATAGGGGGCG GGTTACACAG AATATATAAC
540

ATCGTAGGTG TCTGGGTGAA CAGTTTATCC CTGGCATCCA CTAAATATAA TGGAGCTCGC
600

TTTTAAGCTG GCATCCAGAA AAAAAAGAA TCCCAGCACC AAAATATTGT TTTCTTCACC
660

SUBSTITUTE SHEET

76/79

AACCATCAGT TCATAGGTCC ATTCTCTTAG CGCAACTACA GAGAACAGGG GCACAAACAG

720

GCAAAAAACG GGCACAACCT CAATGGAGTG ATGCAACCTG CCTGGAGTAA ATGATGACAC

780

AAGGCAATTG ACCCAGCAT GTATCTATCT CATTTTCTTA CACCTTCTAT TACCTTCTGC

840

TCTCTCTGAT TTGGAAAAAG CTGAAAAAAA AGGTTGAAAC CAGTCCCTG AAATTATTCC

900

CCTACTTGAC TAATAAGTAT ATAAAGACGG TAGGTATTGA TTGTAATTCT GTAAATCTAT

960

TTCTTAAACT TCTTAAATTC TACTTTTATA GTTAGTCTTT TTTTGTAGTT TAAAACACCA

1020

AGAACTTAGT TTCGAATAAA CACACATAAA CAAACAAAAT GATGGCTCCC GATCCTAATG

1080

CAAATCCAAA TGCAAACCCA AACGCAAACC CCAATGCAAA TCCTAATGCA AACCCCAATG

1140

CAAATCCTAA TGCAAATCCT AATGCCAATC CAAATGCAAA TCCAAATGCA AACCCAAACG

1200

CAAACCCCAA TGCAAATCCT AATGCCAATC CAAATGCAAA TCCAAATGCA AACCCAAATG

1260

CAAACCCCAA TGCAAACCCC AATGCAAATC CTAATAAAAA CAATCAAGGT AATGGACAAG

1320

GTCACAATAT GCCAAATGAC CCAAACCGAA ATGTAGATGA AAATGCTAAT GCCAACAGTG

1380

CTGTAAAAAA TAATAATAAC GAAGAACCAA GTGATAAGCA CATAAAAGAA TATTTAAACA

1440

SUBSTITUTE SHEET

17/19

AAATACAAA TTCTCTTTCA ACTGAATGGT CCCCATGTAG TGTAACCTGT GGAAATGGTA
1500

TTCAAGTTAG AATAAAGCCT GGCTCTGCTA ATAAACCTAA AGACGAATTA GATTATGCAA
1560

ATGATATTGA AAAAAAATT TGTAATATGG AAAAATGTT CAGTGTGTTT AATGTCGTAA
1620

ATAGTTCAAT AGGATTAGGG CCTGTGACGA ACATGGAGAA CATCACATCA GGATTCCTAG
1680

GACCCCTGCT CGTGTTACAG GCGGGGTTTT TCTTGTGAC AAGAATCCTC ACAATACCGC
1740

AGAGTCTAGA CTCGTGGTGG ACTTCTCTCA ATTTTCTAGG GGGATCACCC GTGTGTCTTG
1800

GCCAAAATTC GCAGTCCCCA ACCTCCAATC ACTCACCAAC CTCCTGTCCT CCAATTTGTC
1860

CTGGTTATCG CTGGATGTGT CTGCGGCGTT TTATCATATT CCTCTTCATC CTGCTGCTAT
1920

GCCTCATCTT CTTATTGGTT CTTCTGGATT ATCAAGGTAT GTTGCCCGTT TGTCTCTTAA
1980

TTCCAGGATC AACAACAACC AATACGGGAC CATGCAAAAC CTGCACGACT CCTGCTCAAG
2040

GCAACTCTAT GTTCCCTCA TGTGCTGTA CAAAACCTAC GGATGGAAAT TGCACCTGTA
2100

TTCCCATCCC ATCGTCTTGG GCTTTCGCAA AATACCTATG GGAGTGGGCC TCAGTCCGT
2160

TCTCTTGGCT CAGTTTACTA GTGCCATTTG TTCAGTGGTT CGTAGGGCTT TCCCCACTG
2220

18/19

TTTGGCTTTC AGCTATATGG ATGATGTGGT ATTGGGGGCC AAGTCTGTAC AGCATCGTGA
2280

GTCCCTTTAT ACCGCTGTTA CCAATTTTCT TTTGTCTCTG GGTATACATT TAACGAATTC
2340

CAAGCTGAAA CAATTCAAAG GTTTTCAAAT CAATCAAGAA CTTGTCTCTG TGGCTGATCC
2400

AAACTACAAA TTTATGCATT GTCTGCCAAG ACATCAAGAA GAAGTTAGTG ATGATGTCTT
2460

TTATGGAGAG CATTCCATAG TCTTTGAAGA AGCAGAAAAC AGATTATATG CAGCTATGTC
2520

TGCCATTGAT ATCTTTGTTA ATAATAAAGG TAATTTCAAG GACTTGAAAT AATCCTTCTT
2580

TCGTGTTCTT AATAACTAAT ATATAAATAC AGATATAGAT GCATGAATAA TGATATACAT
2640

TGATTATTTT GCAATGTCAA TTAAAAAAA AAAATGTTAG TAAAACTATG TTACATTCCA
2700

AGCAAATAAA GCACTTG GTT AAACGAAATT AACGTTTTTA AGACAGCCAG ACCGCGGTCT
2760

AAAAATTTAA ATATACACTG CCAACAAATT CCTTCGAGTT GTCCAATTTC ACCACTTTTA
2820

TATTTTCATC AACTTCAGCA GATTCAACCT TCTCACATAG AACATTGGAA TAAACAGCCT
2880

TAACACCACT TTCAAGTTTG CACAGCGTAA TATGAGGAAT TTTGTTTTGA CAACACAACC
2940

CTTTAATTTT CTCATTGTTT TCATCAATTA TGCATCCATC TTTATCTTTA GACAGTTCCA
3000

19/19

CTACAATAGC AATAGTTTTT TCATCCCAAC ATAGTTTTTC GAGCCTAAAA TTCAGTTTGT
3060

CGGTCGTTTT TACCTGCGTA TTTTGGTTAT TACCAGAGCC TTGTGCATTT TCTATGCGGT
3120

TGTTATTGTA CTCCGTTATC TGGTCAGTGT ATCTGTTACA ATATGATTCC ACAACTTTTT
3180

TGCCTCTTTT TCACGGGACG ACATGACATG ACCTAATGTT ATATGAAGTT CCTTCTGAAC
3240

TTTTCCACTA GCTAGTAAAT GCTTGAATTT CTCAGTCAGC TCTGCATCGC TAGCAATACA
3300

CCTCTTGACC AATTCAATAA TTTCATCGTA GTTTTCTATT TAGCTGAGAT ATATGTAGGT
3360

TTAATTAAC TACGTTTTTT TGTTGATTAT TGTTGCCTTT ACCAACTATT TTTCTCACAG
3420

TAGGTTTGTA ATCTAAGCTC CTTCTGAACG CTGTCTCAAT TTCATCATCT TTCGGGATCT
3480

CTGGTACCAA AATTGGATAA GCTT
3504

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 92/02591

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C07K15/00; C12N7/04		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07K ; C12N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
T	<p>AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE vol. 47, no. 4 SU, 1992, USA pages 96 - 97 WHITE, K. ET AL. 'Induction of cytolytic T cells by recombinantly co-expressed circumsporozoite protein fragment of Plasmodium falciparum and Hepatitis B particles' abstract no 19 see abstract & 41st annual meeting of American Society of Tropical Medicine and Hygiene 15-19 november 1992 Seattle, WASHINGTON, USA</p> <p style="text-align: center;">---</p> <p style="text-align: right;">-/--</p>	1
<p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
10 FEBRUARY 1993		20. 02. 93
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		CHAMBONNET F.J.

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	EP,A,0 175 261 (CHIRON CORPORATION) 26 March 1986 see the whole document	1-3, 9-14, 17-20,22
Y	EP,A,0 278 940 (SMITH KLINE- RIT SOCIETE ANONYME) 17 August 1988 see the whole document	1-3, 9-14, 17-20,22
Y	WO,A,8 810 300 (MEDICO LABS AG) 29 December 1988 see claims 4,12,13,19,26	1-3, 9-14, 17-20,22
Y	US,A,4 722 840 (VALENZUELA, P.D.T., KUO, G. & BARR, P.J.) 2 February 1988 see the whole document	1-3, 9-14, 17-20,22
Y	EP,A,0 343 460 (F.HOFFMANN- LA ROCHE) 29 November 1989 see the whole document	1-3, 9-14, 17-20,22
Y	US,A,4 886 782 (GOOD, M.A., BERZOFKY, J., MILLER, L.H.) 12 December 1989 see the whole document	1-3, 9-14, 17-20,22
Y	WO,A,9 000 402 (THE UNITED STATES OF AMERICA) 25 January 1990 see the whole document	1-3, 9-14, 17-20,22

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 92/02591

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 21A are directed to a method of treatment of the human body the search has been carried out and based on the alleged effects of the compound/composition
(Claim 21A due to the fact that there are two claims having number 21)
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

EP 9202591
SA 66853

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 10/02/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0175261	26-03-86	CA-A- 1263618	05-12-89
		DE-A- 3584866	23-01-92
		JP-A- 61129135	17-06-86
		US-A- 4722840	02-02-88
EP-A-0278940	17-08-88	AU-A- 1093088	04-08-88
		JP-A- 1063382	09-03-89
		OA-A- 8801	31-03-89
		SU-A- 1746887	07-07-92
WO-A-8810300	29-12-88	AU-A- 1985588	19-01-89
		AU-A- 1995888	19-01-89
		WO-A- 8810301	29-12-88
		EP-A- 0299242	18-01-89
		EP-A- 0304578	01-03-89
		EP-A- 0300213	25-01-89
		JP-T- 2501186	26-04-90
		JP-T- 2501187	26-04-90
US-A-4722840	02-02-88	CA-A- 1263618	05-12-89
		DE-A- 3584866	23-01-92
		EP-A, B 0175261	26-03-86
		JP-A- 61129135	17-06-86
EP-A-0343460	29-11-89	AU-B- 627459	27-08-92
		AU-A- 3504689	30-11-89
		JP-A- 2042099	13-02-90
		US-A- 5114713	19-05-92
US-A-4886782	12-12-89	None	
WO-A-9000402	25-01-90	US-A- 5028425	02-07-91
		AU-A- 4039089	05-02-90
		EP-A- 0423238	24-04-91